Lv41
500 积分 2021-11-10 加入
Real-world efficacy of zanidatamab in patients with HER2 positive advanced biliary tract cancers
12小时前
待确认
An evaluation of zanidatamab, a novel, anti-HER2 biparatopic antibody, for the treatment of biliary tract cancer
18天前
已完结
HER2-Targeted Therapies: Unraveling Their Role in Biliary Tract Cancers
18天前
已完结
Efficacy and safety of radiotherapy versus transarterial chemoembolization in combination with lenvatinib and camrelizumab for hepatocellular carcinoma with inferior vena cava/right atrium tumor thrombus: a multicenter study
1个月前
已完结
Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in intermediate or advanced, but not early, stages
1个月前
已完结
Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer
1个月前
已完结
Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trial
1个月前
已完结
Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trial
1个月前
已完结
Navigating established and emerging biomarkers for immune checkpoint inhibitor therapy
2个月前
已完结
Maximizing the Conspicuity of CSF-Venous Fistulas on CT Myelography: Assessment of Contrast Density and Timing Effects
2个月前
已完结
皖公网安备34019202002308
